Milton Werner - Inhibikase TherapeuticsInc President CEO
| IKT Stock | USD 1.31 0.05 3.68% |
CEO
Milton Werner is President CEO of Inhibikase TherapeuticsInc
| Age | 60 |
| Address | 3350 Riverwood Parkway SE, Atlanta, GA, United States, 30339 |
| Phone | 678 392 3419 |
| Web | https://www.inhibikase.com |
Milton Werner Latest Insider Activity
Tracking and analyzing the buying and selling activities of Milton Werner against Inhibikase TherapeuticsInc stock is an integral part of due diligence when investing in Inhibikase TherapeuticsInc. Milton Werner insider activity provides valuable insight into whether Inhibikase TherapeuticsInc is net buyers or sellers over its current business cycle. Note, Inhibikase TherapeuticsInc insiders must abide by specific rules, including filing SEC forms every time they buy or sell Inhibikase TherapeuticsInc'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Milton Werner over two weeks ago Acquisition by Milton Werner of 45000 shares of Inhibikase TherapeuticsInc at 2.16 subject to Rule 16b-3 | ||
Milton Werner over a month ago Acquisition by Milton Werner of 210000 shares of Inhibikase TherapeuticsInc at 0.74 subject to Rule 16b-3 |
Inhibikase TherapeuticsInc Management Efficiency
The company has Return on Asset of (0.6367) % which means that on every $100 spent on assets, it lost $0.6367. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.1888) %, meaning that it generated no profit with money invested by stockholders. Inhibikase TherapeuticsInc's management efficiency ratios could be used to measure how well Inhibikase TherapeuticsInc manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.38 in 2024. Return On Capital Employed is likely to gain to -1.72 in 2024. At this time, Inhibikase TherapeuticsInc's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 18.3 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 85.6 K in 2024.Similar Executives
| Found 10 records | CEO Age | ||
| Richard Cunningham | Anebulo Pharmaceuticals | 53 | |
| John Tucker | Scpharmaceuticals | 61 | |
| Gareth Sheridan | Nutriband | 34 | |
| Dietrich MBA | DiaMedica Therapeutics | 53 | |
| Mohamed Hashad | Longeveron LLC | 62 | |
| Dr MBA | Oncolytics Biotech | N/A | |
| MS MD | aTyr Pharma | 52 | |
| Joseph MBA | Milestone Pharmaceuticals | 56 | |
| LLM JD | Tempest Therapeutics | 54 | |
| Eric MBA | Seres Therapeutics | 48 | |
Management Performance
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.64 |
Inhibikase TherapeuticsInc Leadership Team
Elected by the shareholders, the Inhibikase TherapeuticsInc's board of directors comprises two types of representatives: Inhibikase TherapeuticsInc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Inhibikase. The board's role is to monitor Inhibikase TherapeuticsInc's management team and ensure that shareholders' interests are well served. Inhibikase TherapeuticsInc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Inhibikase TherapeuticsInc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roger Rush, Head Research | ||
| Milton Werner, President CEO | ||
| BSc FRCPC, Interim Advisor | ||
| Garth LeesRolfe, Chief Officer | ||
| Joseph CPA, Chief Officer | ||
| Surendra Singh, Manufacturing Chemistry | ||
| Dan Williams, Controller |
Inhibikase Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Inhibikase TherapeuticsInc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.64 | ||||
| Current Valuation | (3.82 M) | ||||
| Shares Outstanding | 6.48 M | ||||
| Shares Owned By Insiders | 13.85 % | ||||
| Shares Owned By Institutions | 10.17 % | ||||
| Number Of Shares Shorted | 135.25 K | ||||
| Price To Book | 1.31 X | ||||
| Price To Sales | 55.21 X | ||||
| Revenue | 260.5 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibikase TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. For more information on how to buy Inhibikase Stock please use our How to Invest in Inhibikase TherapeuticsInc guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Inhibikase Stock analysis
When running Inhibikase TherapeuticsInc's price analysis, check to measure Inhibikase TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase TherapeuticsInc is operating at the current time. Most of Inhibikase TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Inhibikase TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase TherapeuticsInc's price. Additionally, you may evaluate how the addition of Inhibikase TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is Inhibikase TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inhibikase TherapeuticsInc. If investors know Inhibikase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inhibikase TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.57) | Revenue Per Share 0.049 | Quarterly Revenue Growth (1.00) | Return On Assets (0.64) | Return On Equity (1.19) |
The market value of Inhibikase TherapeuticsInc is measured differently than its book value, which is the value of Inhibikase that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibikase TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Inhibikase TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibikase TherapeuticsInc's market value can be influenced by many factors that don't directly affect Inhibikase TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibikase TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inhibikase TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibikase TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.